The combination of artesunate and mefloquine is currently one of the most effective treatments against multidrug-resistant Plasmodium falciparum malaria. To improve patient compliance to such a combination, the two agents have been combined in a prepacked single blister. Patients were instructed to simultaneously co-administer the drugs once a day for three days. In the present randomized, double-blind, parallel group, comparative, single center study in Thailand, this concept was investigated in 204 adults and children with acute, uncomplicated P. falciparum malaria. Patients were randomized into two treatment groups and received once a day over a three-day period the following: Group A received artesunate, 4-5 mg/kg/day, and mefloquine, total dose ‫ס‬ 25 mg/kg, ∼8.5 mg/kg/day, simultaneously. Group B received artesunate, 4-5 mg/kg/day, and mefloquine, total dose ‫ס‬ 25 mg/kg, sequentially (i.e., no mefloquine dose on the first day, 15 mg/kg on the second day, and 10 mg/kg on the third day). Both treatment groups showed no relevant differences in baseline demographic and clinical characteristics. Intent-to-treat analysis revealed a cure rate at day 28 (primary endpoint) of 100% in group A and 99% in group B (difference not significant). The secondary endpoints of mean time to fever clearance (group A ‫ס‬ 34 hours, group B ‫ס‬ 31 hours) and mean time to parasite clearance (group A ‫ס‬ 44 hours group B ‫ס‬ 48 hours) were similar between groups (both differences not significant). Tolerability was good in both treatment groups, with no difference in the overall incidence of adverse events. There was a low incidence of nausea/vomiting (4.9% in both groups) and central nervous system side effects (4.9% in group A versus 8.8% in group B). These were comparable between groups and generally of a mild nature. The three-day combination of artesunate and mefloquine (Artequin, Mepha, Ltd., Aesch, Switzerland) with the introduction of mefloquine on day 1 offers a practical dosing regimen that is highly effective and well tolerated in patients of different ages with uncomplicated P. falciparum malaria. It is likely that the prepacked blister approach translates clinically into a better patient compliance, thereby contributing to limit the development of drug resistance.
INTRODUCTION
Almost one-third of the world's population lives in areas at risk for malaria, and morbidity and mortality from Plasmodium falciparum malaria are steadily increasing in many tropical areas. This development results primarily from the spread of drug resistance in P. falciparum against the previous mainstay antimalarial drug chloroquine and its successor sulfadoxine-pyrimethamine. 1 The most resistant isolates of P. falciparum are found today in areas of southeast Asia. 2 One of the few efficacious treatments for uncomplicated but highly multidrug-resistant P. falciparum infections encountered in some areas is the combination of an artemisinin derivative, such as artesunate, with mefloquine. 3, 4 Artesunate is very well tolerated, but to be effective when used alone treatment for at least five days is required. 5, 6 When used alone recrudescence rates on the order of 10-20% have been reported, which may be attributable to the relatively short half-life of the compound. 7, 8 Mefloquine was introduced in the 1980s and remains effective in most endemic areas for both treatment and prophylaxis of malaria. The drug is generally well tolerated, but may be occasionally associated with neuropsychiatric adverse effects. 9, 10 A series of controlled studies showed high efficacy rates and good tolerability for the artesunate/mefloquine combination, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and consequently, it has become a standard regimen for the treatment of uncomplicated malaria in southeast Asia. However, treatment strategies differ in terms of treatment dura-tion (from one day 13 to five or more days 18 ), and in terms of dosing. Mefloquine is customarily introduced only on the second day of the course because early side effects are suspected. Conventionally, the drugs have to be combined from different packages, which may pose logistical problems and might compromise patient compliance. Preliminary data have shown that provision of blister packs of daily doses of artesunate and mefloquine is an effective way to improve compliance with drug combinations, while maintaining high therapeutic efficacy. 21 The aim of our study was to investigate the efficacy and safety of a blister-prepacked artesunate/mefloquine combination (brand name of the blister pack in which both drugs are distributed together is Artequin, manufactured by Mepha, Ltd., Aesch, Switzerland) administered once a day for three days, with mefloquine starting already on day 1. This regimen was compared with a conventional sequential combination regimen with the first day of treatment consisting of a single once a day dose of artesunate, followed by two days of once a day co-administration of artesunate and mefloquine.
MATERIALS AND METHODS

Study site.
The study was undertaken between March and July 2001 at the Bangkok Hospital for Tropical Diseases (Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand). Informed consent was obtained from all human adult participants and from parents or legal guardians of minors, with an appropriate institutional review board having approved the project. The protocol was approved by the Ethics Committee of the Faculty of Tropical Medicine of the Mahidol University in Bangkok, and conducted according to the Declaration of Helsinki with all its amendments.
Study participants. Patients presenting with the symptoms suggestive of malaria were consecutively assessed for the following inclusion criteria: 1) male or female with a weight greater than 25 kg; 2) the presence of acute, uncomplicated P. falciparum malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. falciparum (i.e., identification of asexual parasite count between 100 and 400,000/ L of blood); 3) the ability to take oral medication; 4) a willingness to stay in the hospital for 28 days, or at least for seven days and able to come back once a week for the next three weeks; and 5) written informed consent provided by the patient or parents/guardian.
The following exclusion criteria applied: 1) patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment, defined according to the World Health Organization (WHO) Criteria of 2000; 22 2) severe vomiting and an inability to tolerate oral treatment; 3) known hypersensitivity or allergy to artemisinin derivatives, mefloquine, or mefloquine chemically related compounds (e.g., quinine and quinidine); 4) any other antimalarial drug therapy within two weeks prior to the start of the study; 5) use of investigational (unlicensed) drugs within 30 days prior to the start of the study; 6) a known history of psychiatric disorders or convulsions; 7) a known history of cardiac diseases or arrhythmia; 8) liver function test results (alanine aminotransferase/aspartate aminotransferase [ALAT/ASAT] levels) more than three times above the upper limit of normal values; and 9) pregnancy or lactation.
Randomization and blinding. On day 0, eligible patients were randomized to treatment groups on the basis of a computer-generated randomization list. The investigational therapy in Group A consisted of artesunate, 4-5 mg/kg/day, and mefloquine, total dose ‫ס‬ 25 mg/kg, (∼8.5 mg/kg/day), given in equal doses simultaneously once a day over a threeday period. The reference therapy in Group B was artesunate, 4-5 mg/kg/day, and mefloquine, total dose ‫ס‬ 25 mg/kg given sequentially (i.e., no mefloquine dose on the first day, 15 mg/kg on the second day, and 10 mg/kg on the third day) over a three-day period. Artesunate (Plasmotrim-200 and -50 Lactab), mefloquine (Mephaquin-250 Lactab), and placebo to mefloquine were supplied by Mepha, Ltd. (Aesch, Switzerland) in Good Manufacturing Practice (GMP) quality and were provided in prepacked blisters. One blister contained all tablets for the three-day treatment period. Each patient's treatment consisted of one box containing two blisters, one primary medication blister and one replacement medication blister to be used only in case of early vomiting. According to WHO guidelines for antimalarial treatment based on body weight and age, patients were stratified into three different dosing groups: body weight > 50 kg (corresponding to those approximately > 15 years old), body weight ‫ס‬ 36-50 kg (those approximately 11-15 years old), and body weight ‫ס‬ 25-35 kg (those approximately 8-10 years old). Body weight took preference over age to determine in which dosing group the patient was to be stratified. The daily doses of artesunate (4-5 mg/kg/day) and the total dose of mefloquine (25 mg/kg) combined in this study were the same doses as the ones recommended for monotherapy in the approved labels for both drugs. A detailed dosing scheme based on body weight is shown in Table 1 .
All daily doses were taken at the hospital under the supervision of the investigator or one of the co-investigators. All tablets were to be taken without chewing and with approximately 250 mL of water and, if possible, with a meal. If patients had difficulties swallowing, the tablets were crushed and dissolved in a small quantity of water. If vomiting occurred within 30 minutes after intake, the entire investigational drug dose was to be administered again. If vomiting occurred between 30 and 60 minutes after intake, half of the dose was then replaced. To avoid any bias in the evaluation of efficacy and side effects, the study was conducted in a doubleblind fashion.
The blinding of the study was preserved by using identical medication, in terms of smell and appearance, in both treatment arms. This was done by using Mephaquin placebo Lactab in both treatments. The randomization was generated by an independent statistician. He was the only one who had access to it until locking of the database. The investigator received a sealed code envelope for each patient with the details of drug treatment included in it. Only in case of an emergency was the envelope to be opened to determine the treatment given.
Clinical and laboratory assessments. Medical history and drug history were assessed at the baseline examination. A full physical examination was carried out at baseline and at days 4, 7, and 28. Vital signs assessed at each visit included systolic and diastolic blood pressure using a sphygmomanometer, recording of the pulse rate with the patient in the supine position for at least three minutes, and measurement of the body temperature using a standard clinical thermometer retained in the mouth for two minutes before reading. The physical examination included a brief neurologic examination with tests for coordination (e.g., heal-toe ataxia), fine finger dexterity (e.g., ability to pick up a 500-mg paracetamol tablet), hearing (e.g., using a 256-Hz tuning fork), as well as an assessment for nystagmus and balance (e.g., assessment of sway with the eyes closed). A 12-lead electrocardiogram was recorded at baseline and at days 7 and 28. A pregnancy test using a urine dipstick was done in women of childbearing potential (Ն 12 years) at baseline and at day 28.
Laboratory measurements were performed at baseline and on days 2, 4, 7, and 28. They included hematology (hemoglobin, hematocrit, red blood cells, total white blood cells, differential count, reticulocytes, and platelets), biochemistry (total bilirubin, alkaline phosphatase, ALSAT, ALAT, sodium, potassium, fasting glucose, urea, creatinine, and albumin), and urine dipstick tests (albumin, glucose, and blood).
Parasitologic examination consisted of a thick and thin blood film prepared every 12 hours until the blood film was negative. Thereafter, smears were prepared daily up to day 7 and then weekly on days 14, 21, and 28. Blood films were considered negative if no parasites were seen in 200 oilimmersion fields in a thick blood film. Thin films were counted per 1,000 red blood cells and thick films were counted per 200 white blood cells. The number of malaria parasites per microliter of blood was assessed repeatedly against the number of red blood cells and white blood cells. In cases where thick blood films were missing or uncountable (too many parasites), the number of malaria parasites was calculated using a thin blood film and red blood cells. Parasitologic examination was performed for all randomized patients, regardless of whether or not they discontinued study medication.
Outcome measures. The standard primary parameters for evaluating efficacy of antimalarials measure the extent and the speed of parasite elimination, both of which are essential for therapeutic success. 23 The 28-day cure rate was chosen as primary efficacy endpoint and was defined as: proportion of patients with clearance of asexual parasitemia within seven days of initiation of study treatment, without subsequent recrudescence within 28 days after start of the study (Intent-To-Treat [ITT] analysis). Recrudescence was defined as further clinical manifestation of infection (i.e., clinical signs and symptoms of uncomplicated malaria with a positive blood smear) after initial clearance of parasites from the peripheral blood. Patients with only a positive blood smear and no signs and symptoms were regarded as recrudescence. Conversely, only signs and symptoms in the context of a negative blood smear were not considered a recrudescence.
Secondary efficacy endpoints (ITT analysis) were 1) the 14-day cure rate; 2) time to parasite clearance (time from the first dose until the first total and continued disappearance of asexual parasite forms that continued for at least an additional 24 hours); 3) time to fever clearance (time from the first dose until the first body temperature decreased and remained less than 37.5°C for at least an additional 24 hours); 4) parasite reduction during the first 72 hours (measured as the num-ber of patients with a negative blood smear on days 2, 3, and 4); and 5) time to gametocyte clearance (time from the first dose until the first and continued disappearance of gametocytes that continued for at least an additional 24 hours). Gametocyte clearance was determined only in those patients showing gametocytes at baseline.
Safety assessments consisted of monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs), physical examinations, regular monitoring of hematology, blood chemistry and urine parameters, as well as regular recordings of vital signs. The primary safety endpoint was the incidence of vomiting and central nervous system side effects.
Statistical analysis. The ITT population included all randomized patients that took at least one dose of study medication and the per protocol (PP) population (i.e., evaluable patients), which is all patients of the ITT population who did not violate the protocol. The ITT population was used for analysis of background variables and for the primary and secondary endpoints. Missing data were imputed by using the Last Observation Carried Forward method, except for survival analyses. The population used for safety analyses was identical with the ITT population in this study. For efficacy evaluation, a pairwise treatment comparison was performed comparing the 28-day cure rates of the two treatment groups by means of a chi-square test (P Յ 0.05). Parasite and fever clearance times were evaluated by survival analysis. Survival data were compared by using Kaplan-Meier plots and the Mantel-Haenszel log rank test. For AEs occurring in more than 5% of patients and for the events vomiting, dizziness, abdominal pain, and nausea, pairwise treatment comparisons by means of a chi-square test (P Յ 0.05) were performed. All analyses were done with SAS (Cary, NC) software.
On the basis of a 28-day cure rate of approximately 90% for standard antimalarial regimens (sequential treatment group B), new treatment should be within 10% of the efficacy of the standard treatment. With a relevant difference of 10%, the resulting sample size is 100 per group. That sample size would allow one to detect a 10% difference between the two active treatments with a two-sided chi-square test (␣ ‫ס‬ 0.05).
RESULTS
Demographic and background characteristics.
A total of 204 patients (102 in each treatment group) were enrolled in the study (Figure 1 ). There was no protocol deviation regarding inclusion and exclusion criteria or randomization, respectively, and treatment allocation was kept blinded throughout the duration of the study. All protocol deviations and irregularities detected during the study were classified as minor and had no impact on the safe conduct of the study or on the interpretation of the results. All but one patient completed the study. Only one patient in group A was lost to follow-up after day 7. Since he was already cured on day 7, this observation was carried forward for the ITT analysis. One patient in group B (dosing group > 50 kg) discontinued study medication on day 1 due to an SAE (hypotension). He received another antimalarial medication, completed the study as planned, and was included in the ITT population. All code envelopes remained sealed. As prospectively defined in the statistical analysis plan, no PP analysis has been conducted because the number of patients in the PP population deviated less than 5% from the ITT population.
The baseline characteristics of the randomized patients are shown in Table 2 . A total of 156 male and 48 female patients (age range ‫ס‬ 8-63 years) participated in the study. The distribution of demographic characteristics was not significantly different between the two treatment groups. No patient had a significant medical history, concomitant diseases, or baseline physical examination results that could have interfered with the objectives of the study. The baseline physical examination results and the concomitant diseases reported reflected the signs and symptoms of the underlying malaria infection. A total of 70 patients (30 patients in treatment group A [29.4%] and 40 patients in treatment group B [39.2%]) reported gastrointestinal signs and symptoms at baseline. Overall, the distribution of clinical baseline characteristics was comparable between the two treatment groups and between the different age/dosing groups. There was a statistically significant difference (P ‫ס‬ 0.031) between the mean numbers of P. falciparum asexual forms per microliter of blood at baseline in group A (27, 624 [range ‫ס‬ 105-155,040]) compared with group B (40,045 [range ‫ס‬ 114-219,350]). However, this had no impact on the primary efficacy endpoint.
Twelve patients (5.9%, six patients in each group) had received previous antimalarial medication with end of treatment at least two weeks before the start date of study medication. The most frequently used concomitant medications were analgesics and antipyretics. Actually, all patients received antipyretic drugs within the first three days of study medication intake. The most commonly used antipyretic was paracetamol (96.6%). Some patients received other unspecified analgesics and antipyretics; however, there were no differences between the groups. All concomitant medications are commonly used at the study center for symptomatic treatment of malaria. The class of drugs and the usage were similar between the two treatment groups and were used mainly to treat the initial signs and symptoms of the underlying malaria infection.
Efficacy. The outcomes for the primary and secondary efficacy endpoints are shown in Table 3 . Both treatment regimens were highly efficacious: difference not significant. All but one patient (treatment group B, 36-50 kg body weight group) were cured at day 28. For the secondary endpoints, there were no statistically significant differences between the treatment groups, with two exceptions of no clinical relevance (see Table 3 ). Mean time to parasite clearance was achieved quickly (44 hours in group A versus 48 hours in group B), as was the mean time to fever clearance (34 hours in group A versus 31 hours in group B). Time to total parasite clearance by treatment group is illustrated by a Kaplan-Meier plot in Figure 2 . Figure 3 shows the curves for the time to fever clearance, a parameter that generally corresponds well to the improvement in the patients' well-being.
Only 31 patients presented with gametocytes at baseline (16 in group A and 15 in group B). The mean time to gametocyte clearance was not significantly different between the groups.
Blood smears were also analyzed for other parasites. Two patients in group A (36-50 kg dosing group) presented with a mixed infection of P. falciparum and P. vivax at baseline. By the end of day 2, both parasite species were cleared from the blood of these two patients.
Safety. Only one SAE was reported during the study duration. A 33-year-old patient in group B experienced a hypovolemic shock 30 minutes after the first dose of study medication, probably related to dehydration. The patient recovered without sequelae after three days of symptomatic treatment. The relationship to study drug was rated as "unlikely" by the investigator.
Sixty-six patients had AEs. All patients with AEs recovered without sequelae. The relationship of all AEs to study medication was rated by the investigators as "unlikely." The system organ classes most commonly affected were metabolism and nutritional disorders, "gastrointestinal disorders," and "nervous system" disorders (Table 4 ). No AE showed a statistically significant difference in occurrence between treatment groups. In particular, there was no difference in the overall incidence of vomiting. Early vomiting occurred in only two patients in treatment group A. Both patients received the replacement medication.
Hematologic and biochemical parameters were comparable at baseline, and there were no clinically meaningful differ-FIGURE 2. Time to total parasite clearance by treatment group in the intent-to-treat population. The solid line represents group A (simultaneous artesunate/mefloquine therapy, n ‫ס‬ 102). The dashed line represents group B (sequential artesunate/mefloquine therapy, n ‫ס‬ 102). Total parasite clearance was defined as the number of patients with a negative blood smear calculated using a thick blood film and white blood cells. If the thick blood film was missing or uncountable (too many parasites), the number of malaria parasites was calculated using a thin blood film and red blood cells. ences between the treatment groups for any of the variables during the course of the study. However, in 13 patients in group A and 19 patients in group B (difference not significant), hypokalemia was rated as an AE most likely caused by malaria-induced disturbances of the water-electrolyte balance. Moreover, no clinically significant changes in vital signs and electrocardiograms were noted during the study. All patients had regular specific neurologic examinations during the study. No patients had any abnormal neurologic findings. The overall tolerability of the treatment as assessed by the investigators at day 28 was judged to be very good for almost all patients in both treatment groups (101 and 100 patients in group A and B, respectively). All results of pregnancy tests were negative.
DISCUSSION
The main outcome of our study was that a three-day treatment course with artesunate/mefloquine co-administered once a day in identical daily dosages from the first day of therapy is both highly effective and well tolerated in the treatment of acute, uncomplicated, P. falciparum malaria in Thailand. It is as effective and safe as the currently applied sequential artesunate/mefloquine treatment regimen in multidrug-resistant areas in Asia. The age of the patient had no impact on this assessment. Rapid parasite and fever clearances were achieved. The cure rate after 28 days of 100% is similar to those that have been reported for artesunate/ mefloquine combinations in previous Asian studies through- out the last 10 years. It also matches those of a double-blind study with almost identical design and the same investigational agents in 104 patients in west and central Africa. 24 Of particular clinical importance is the short time to fever clearance, on average less than two days, which is a typical feature of therapy with artemisinin derivatives. Treatment with these most potent and rapidly acting of the antimalarial drugs 25 carries the danger that the rapid alleviation of symptoms may lead to truncated regimens with subsequent development of drug resistance. 26 In some regions, mefloquine, the most studied drug of all antimalarials, 10 tends to have decreased efficacy due to resistance when used in monotherapy.
Excellent efficacy results can be achieved when both agents are used in combination. Of a variety of potential antimalarial combinations, the greatest amount of safety and efficacy data available concerns the combination of artesunate/mefloquine. 27 The key advantage expected for combination therapy of both drugs is, apart from the high efficacy and good tolerability, prevention of the development of drug resistance. This is based on the fact that even if a single dose of an artemisinin derivative is given, the total number of parasites surviving is still 0.01% of those present originally. 28 It is important to note that even after several treatment cycles, parasites may survive. With the use of artesunate/mefloquine combination therapy, these remaining parasites are then exposed to therapeutic blood mefloquine concentrations over a long period of time (half-life of mefloquine ‫ס‬ 2-3 weeks), which will eliminate these parasites. Thus, the high potency of artesunate, which might be compromised by its short half-life, is counterbalanced by mefloquine, which has a long half-life. Indeed, the general introduction of the three-day combined artesunate/mefloquine regimen for all cases of P. falciparum malaria in Thailand had impressive consequences: since 1998, the cure rate with this regimen has been close to 100% (95% confidence interval ‫ס‬ 97-100%). 1 No comparable period of sustained high efficacy for any antimalarial regimen has been reported in this population for the past 15 years. 29 Moreover, recent observations in southeast Asia, especially on Thailand's border with Cambodia and Myanmar, suggest that the highly efficacious combination therapy has halted a rapid decrease in the efficacy of mefloquine and may have reduced overall malaria transmission. 11, 28, 29 The safety observations in our study are of particular interest, since tolerability of the regimen is a crucial determinant for patient compliance. The overall safety profile of the combination of artesunate and mefloquine was very good irrespective of patient age and reflected the well-known profiles of both drugs when used as monotherapy. The AE pattern matched the one known from previous experience from other Asian studies.
Our study showed that mefloquine can be safely administered from the first day of therapy onwards, thus simplifying the regimen for patients. Increased mefloquine-related vomiting has been described in the literature when treatment already starts on day 1. 3, 29 However, in our study this was not observed with the co-administration of both drugs from the first day and the chosen doses were obviously tolerable ones. In terms of central nervous system side effects, the incidences were comparable between treatment groups. Moreover, specific neurologic examinations during the study revealed no abnormal findings.
In conclusion, artesunate and mefloquine can be co-administered from the first day of therapy. The treatment regimen once a day for three days offers optimal efficacy while maintaining good safety and tolerability, independent from age. It is likely that the convenient blister packing of these drugs will enhance patient compliance and thus contribute to limit the development of drug resistance.
